FDA declines pediatric EUA to Covaxin

Written by Medical Dialogues Bureau Published On 2022-03-05T14:56:14+05:30 | Updated On 5 March 2022 2:56 PM IST

New Delhi: Ocugen Inc (OCGN.O) said on Friday U.S. regulators have declined to issue an emergency use authorization (EUA) for Covaxin, the COVID-19 vaccine developed by its Indian partner Bharat Biotech, for use in individuals aged 2 to 18 years.

Shares of Ocugen slumped 30% premarket on the news.

Also Read:USFDA accepts Bristol Myers Squibb's Application for Opdivo

Ocugen said it intends to continue working with the U.S. Food and Drug Administration to evaluate the process for getting an EUA for pediatric use of Covaxin.

Ocugen had entered into a deal with vaccine maker Bharat Biotech in late 2020, under which it would develop, supply, and commercialize Covaxin for the US market.

Covaxin, which is not cleared for any age group in the United States, is one of the two most widely used COVID vaccines in India and also has an emergency use listing from the World Health Organization.

Also Read:Lupin gets USFDA nod for Sevelamer Hydrochloride Tablets

Emergency Use Authorizationu s food and drug administrationEUAcovidcovid 19COVID vaccineCovaxinU S Food and Drug AdministrationUSFDAFDAocugenOcugen news

Source : Reuters

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.